/ Ways2Capital : Zydus Nesher Pharmaceuticals Receives Final Approval From USFDA ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 27 February 2017

Cadila Healthcare is currently trading up by 2.78% as Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from USFDA for Oseltamivir Phosphate capsules in strengths of 30mg, 45 mg and 75 mg.

It is an anti viral used in the prevention and treatment of influenza virus infection.The group has also received the final approval from USFDA to market Linezolid Tablets USP, 600mg. The drug is an anti-bacterial agent, used to treat certain serious bacterial infections.

Cadila Healthcare Ltd is currently trading at Rs 440.95, up by Rs 10.9 or 2.53% from its previous closing of Rs 430.05 on the BSE. The scrip opened at Rs 435 and has touched a high and low of Rs 446.7 and Rs 432.5 respectively.So far 1969131(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 44026.05 crore.For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717